TRCT
OKUR

Tower Research Capital (TRC)’s OnKure Therapeutics OKUR Stock Holding History

Tower Research Capital (TRC)’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35K Buy
+1,611
New +$6.91K ﹤0.01% 4137
2025
Q4 		– Sell
-1,935
Closed -$5.32K – 5717
2025
Q3 		$5.32K Buy
1,935
+103
+6% +$255 ﹤0.01% 4245
2025
Q2 		$4.38K Sell
1,832
-392
-18% -$1.03K ﹤0.01% 4336
2025
Q1 		$9.56K Buy
2,224
+23
+1% +$129 ﹤0.01% 3758
2024
Q4 		$18.9K Buy
2,201
+170
+8% +$2.57K ﹤0.01% 3227
2024
Q3 		$34.5K Buy
2,031
+537
+36% +$7.94K ﹤0.01% 2931
2024
Q2 		$22.6K Buy
1,494
+546
+58% +$9.26K ﹤0.01% 3684
2024
Q1 		$15.7K Buy
948
+270
+40% +$4.46K ﹤0.01% 3228
2023
Q4 		$10.8K Buy
678
+530
+358% +$33K ﹤0.01% 4197
2023
Q3 		$11.3K Buy
148
+74
+100% +$5.03K ﹤0.01% 4011
2023
Q2 		$4.85K Sell
74
-174
-70% -$14K ﹤0.01% 4894
2023
Q1 		$15K Sell
248
-344
-58% -$12.5K ﹤0.01% 3834
2022
Q4 		$14K Buy
+592
New +$15.7K ﹤0.01% 3548
2022
Q3 		– Sell
-129
Closed -$3K – 6570
2022
Q2 		$3K Sell
129
-851
-87% -$19.8K ﹤0.01% 5425
2022
Q1 		$29K Buy
980
+856
+690% +$47.9K ﹤0.01% 3204
2021
Q4 		$11K Sell
124
-6
-5% -$441 ﹤0.01% 4472
2021
Q3 		$10K Buy
130
+126
+3,150% +$10.7K ﹤0.01% 4350
2021
Q2 		$0 Buy
+4
New +$446 ﹤0.01% 5912

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s OKUR Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 1,611 shares worth $7.35K. The stake represents ﹤0.01% of the portfolio and ranks #4137 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in OKUR as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in OKUR in Q2 2021 and has held it in 18 quarters since. The position peaked at $34.5K in Q3 2024. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Tower Research Capital (TRC) held 1,611 shares of OnKure Therapeutics worth $7.35K as of Q2 2026.
  • OnKure Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • OnKure Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4137 holding.
  • Tower Research Capital (TRC) first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s OnKure Therapeutics position peaked at $34.5K in Q3 2024.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.